<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">323</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2019-13-4-75-88</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>BASIC RESEARCH</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Study of myelodysplastic features in patients with myelodysplastic syndromes by multicolor flow cytometry</article-title><trans-title-group xml:lang="ru"><trans-title>Изучение признаков дисмиелопоэза методом многоцветной проточной цитофлуориметрии у пациентов с миелодиспластическими синдромами</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5932-0285</contrib-id><name-alternatives><name xml:lang="en"><surname>Davydova</surname><given-names>O. Yu.</given-names></name><name xml:lang="ru"><surname>Давыдова</surname><given-names>Ю. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p>Юлия Олеговна Давыдова </p><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><email>juliya89mur@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8490-6066</contrib-id><name-alternatives><name xml:lang="en"><surname>Galtseva</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Гальцева</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6177-3566</contrib-id><name-alternatives><name xml:lang="en"><surname>Parovichnikova</surname><given-names>E. N.</given-names></name><name xml:lang="ru"><surname>Паровичникова</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0261-5941</contrib-id><name-alternatives><name xml:lang="en"><surname>Kokhno</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Кохно</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6512-910X</contrib-id><name-alternatives><name xml:lang="en"><surname>Kapranov</surname><given-names>N. M.</given-names></name><name xml:lang="ru"><surname>Капранов</surname><given-names>Н. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4827-8947</contrib-id><name-alternatives><name xml:lang="en"><surname>Troitskaya</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Троицкая</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2449-2682</contrib-id><name-alternatives><name xml:lang="en"><surname>Mikhailova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Михайлова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0934-6094</contrib-id><name-alternatives><name xml:lang="en"><surname>Fidarova</surname><given-names>Z. T.</given-names></name><name xml:lang="ru"><surname>Фидарова</surname><given-names>З. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Moiseeva</surname><given-names>T. N.</given-names></name><name xml:lang="ru"><surname>Моисеева</surname><given-names>Т. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6201-6276</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuzmina</surname><given-names>L. A.</given-names></name><name xml:lang="ru"><surname>Кузьмина</surname><given-names>Л. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8774-850X</contrib-id><name-alternatives><name xml:lang="en"><surname>Lukina</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Лукина</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Obukhova</surname><given-names>T. N.</given-names></name><name xml:lang="ru"><surname>Обухова</surname><given-names>Т. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grebenyuk</surname><given-names>L. A.</given-names></name><name xml:lang="ru"><surname>Гребенюк</surname><given-names>Л. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1082-8659</contrib-id><name-alternatives><name xml:lang="en"><surname>Kovrigina</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Ковригина</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9877-0796</contrib-id><name-alternatives><name xml:lang="en"><surname>Dvirnyk</surname><given-names>V. N.</given-names></name><name xml:lang="ru"><surname>Двирнык</surname><given-names>В. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8188-5557</contrib-id><name-alternatives><name xml:lang="en"><surname>Savchenko</surname><given-names>V. G.</given-names></name><name xml:lang="ru"><surname>Савченко</surname><given-names>В. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>4 Novyi Zykovskiy Proezd, Moscow 125167</italic></p></bio><bio xml:lang="ru"><p><italic>125167 Москва, Новый Зыковский проезд, 4</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Center for Hematology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-03" publication-format="electronic"><day>03</day><month>12</month><year>2018</year></pub-date><volume>13</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>75</fpage><lpage>88</lpage><history><date date-type="received" iso-8601-date="2019-01-02"><day>02</day><month>01</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-01-02"><day>02</day><month>01</month><year>2019</year></date></history><permissions><copyright-year>2018</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/323">https://oncohematology.abvpress.ru/ongm/article/view/323</self-uri><abstract xml:lang="en"><p><bold><italic>Background . </italic></bold><italic>Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal diseases of the hematopoiesis system characterized by dismyelopoiesis and cytopenia, the presence of cytogenetic aberrations and a high risk of transformation into acute myeloid leukemias. Diagnosis of MDS requires a comprehensive approach and mandatory performance of cytological, cytochemical and cytogenetic studies of bone marrow aspirate, as well as histological examination of trephine biopsy. However, in some cases it is necessary to undergo a diagnostic test that would allow verification of the MDS. The study of bone marrow aspirate by multicolor flow cytometry (MFC) can be considered as an additional diagnostic criterion in the diagnosis of MDS.<bold/></italic></p><p><bold><italic>The objective </italic></bold><italic>of the study was to estimate the incidence of myelodysplastic features in patients with various forms of MDS by the MFC method. </italic></p><p><bold><italic>Materials and methods . </italic></bold><italic>The study included 79 patients with MDS: 8 with MDS with 5q deletion, 33 with MDS without excess blast cells and 38 with excess of blasts. A bone marrow aspirate test was performed by 6-color flow cytometry. The control group included 35 donors of allogeneic bone marrow. The analysis resulted in a conclusion on the Ogata score scale, the Wells prognostic scale and the combined Ogata–Wells scale. When using the screening method, the presence of two or more cytometric signs of MDS was detected in 60 (75.9 %) of 79 MDS patients. Wells score was higher in MDS group with an excess of blast than in others. Using the combined Ogata–Wells scale, cytometric aberrations were found in 70 (88.6 %) of 79 MDS patients. In patients with MDS with an excess of blasts, the incidence of increased CD34+ and/or CD117+ myeloid cells was higher than in MDS patients without an excess of blasts and an MDS with a 5q deletion. The frequency of abnormal cytometric parameters (anomalous expression of CD34, CD117, CD56+ myeloblasts) in these groups did not differ. In patients with isolated 5q deletion and MDS without excess of blasts, an increased proportion of CD7+CD34+ cells was more often detected than in MDS with an excess of blasts.</italic></p><p><bold><italic>Conclusion . </italic></bold><italic>Thus, cytometric abnormalities in MDS are common, even in patients without excess of blasts. The MFC method can be used as an additional diagnostic method in the initial diagnosis of MDS.<bold/></italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Введение . </italic></bold><italic>Миелодисплаcтические синдромы (МДС) – это гетерогенная группа клональных заболеваний системы кроветворения,характеризующихся дисмиелопоэзом и цитопениями, наличием цитогенетических аберраций и высоким риском трансформации в острые миелоидные лейкозы. Диагностика МДС требует комплексного подхода и обязательного выполнения цитологического, цитохимического и цитогенетического исследований аспирата костного мозга, а также гистологического исследования трепанобиоптата. Однако в случаях цитопенических синдромов с минимальными проявлениями дисмиелопоэза требуется дополнительный диагностический критерий, который позволил бы верифицировать МДС. Исследование аспирата костного мозга методом многоцветной проточной цитофлуориметрии (МПЦ) можно рассматривать как дополнительный критерий в диагностике МДС.</italic></p><p><bold><italic>Цель исследования </italic></bold><italic>– оценка частоты встречаемости признаков дисмиелопоэза у пациентов с различными формами МДС методом МПЦ.<bold/></italic></p><p><bold><italic>Материалы и методы . </italic></bold><italic>В исследование включено 79 пациентов с МДС: 8 – с МДС с изолированной делецией 5q, 33 – с МДС без избытка бластных клеток и 38 – с избытком бластных клеток. Исследование аспирата костного мозга проводили методом 6-цветной проточной цитофлуориметрии. В контрольную группу вошло 35 доноров аллогенного костного мозга. В результате анализа составлялось заключение по скрининговой шкале Ogata score, прогностической шкале Wells и объединенной шкале Ogata–Wells. При применении скринингового метода наличие 2 и более цитометрических признаков МДС было выявлено у 60 (75,9 %) из 79 пациентов c МДС. При использовании более глубокого анализа всех клеточных компартментов показано, что наибольший балл по шкале Wells был у пациентов из группы МДС с избытком бластных клеток. При применении объединенной шкалы Ogata–Wells признаки, характерные для МДС, обнаруживались у 70 (88,6 %) из 79 пациентов c МДС. У пациентов с МДС с избытком бластных клеток частота обнаружения увеличенного количества CD34+ и/или CD117+ миелоидных клеток была выше, чем у больных с МДС без избытка бластных клеток и МДС с делецией 5q. При этом частота обнаружения аномальных цитометрических параметров (аномальная экспрессия CD34, CD117, доля CD56+ миелобластных клеток) в этих группах не отличалась. У пациентов с изолированной делецией 5q и МДС без избытка бластных клеток чаще выявлялась повышенная доля CD7+CD34+ клеток, чем при МДС с избытком бластных клеток.</italic></p><p><bold><italic>Заключение . </italic></bold><italic>Таким образом, цитометрические аномалии при МДС встречаются часто, даже у пациентов без избытка бластных клеток. Метод МПЦ может быть использован в качестве дополнительного диагностического метода при первичной диагностике МДС.<bold/></italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>myelodysplastic syndrome</kwd><kwd>flow cytometry</kwd><kwd>immunophenotyping</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>миелодиспластический сидром</kwd><kwd>проточная цитофлуориметрия</kwd><kwd>иммунофенотипирование</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Swerdlow S.H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition, revised. International Agency for research on Cancer, 2017.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Savchenko V.G., Parovichnikova E.N., Kokhno A.V. et al. National clinical guidelines for the diagnosis and treatment of myelodysplastic syndromes in adults (2015). Gematologiya i transfuziologiya = Hematology and Transfusiology 2016; 61(1S(4)):1–32. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Савченко В.Г., Паровичникова Е.Н., Кохно А.В. и др. Национальные клинические рекомендации по диагностике и лечению миелодиспластических синдромов взрослых (2015 г.). Гематология и трансфузиология 2016 61(1S(4)):1–32. [</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Bowen D., Culligan D., Jowitt S. et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003;120(2):187–200. PMID: 12542475.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Matsuda A., Germing U., Jinnai I., et al. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia 2007;21(4):678–86. DOI: 10.1038/sj.leu.2404571. PMID: 17268513.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Dvirnyk V.N., Kuzmina L.A., Kokhno A.V. et al. Dismyelopoiesis features in patients with myelodysplastic syndromes after allogeneic hematopoietic stem cells transplantation. Gematologiya i transfuziologiya = Hematology and Transfusiology 2014;59(S1):91–2. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Двирнык В.Н., Кузьмина Л.А., Кохно А.В. и др. Особенности дисмиелопоэза у больных миелодиспластическими синдромами после трансплантации аллогеных гемопоэтических стволовых клеток. Гематология и трансфузиология 2014;59(S1):91–2.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Kovrigina A.M., Glinkina S.A., Baikov V.V. Principles of pathomorphological differential diagnosis of myelodysplastic syndromes. Klinicheskaya onkogematologiya = Clinical oncohematology 2015;8(1):62–8 (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Ковригина А.М., Глинкина С.А., Байков В.В. Принципы патоморфологической дифференциальной диагностики миелодиспластических синдромов. Клиническая онкогематология 2015;8(1):62–8.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>Soligo D., Delia D., Oriani A. et al. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody. Leukemia 1991;5(12):1026–30. PMID: 1723130.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Rogers H.J., Vardiman J.W., Anastasi J. et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica 2014;99(5):821–9. DOI: 10.3324/haematol.2013.096420. PMID: 24463215.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Parovichnikova E.N., Pimenova M.A., Kokhno A.V. et al. Chromosomal abnormalities in hematopoietic and stromal progenitor cells in myelodysplastic syndrome. Gematologiya i transfusiologiya = Hematology and Transfusiology 2013;58(4):33–40. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Паровичникова Е.Н., Пименова М.А., Кохно А.В. и др. Хромосомные аномалии в кроветворных и стромальных клетках-предшественницах при миелодиспластическом синдроме. Гематология и трансфузиология 2013;58(4): 33–40.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Davydova Yu.O., Galtseva I.V., Kokhno A.V., Parovichnikova E.N. Multicolor flow cytometry as a diagnostic tool in myelodysplastic syndromes. Onkogematologiya = Oncohematology 2018;13(1):63–72 (In Russ.). DOI: 10.17650/1818-8346-2018-13-1-63-72.</mixed-citation><mixed-citation xml:lang="ru">Давыдова Ю.О., Гальцева И.В., Кохно А.В., Паровичникова Е.Н. Роль многоцветной проточной цитофлуориметрии в диагностике миелодиспластических синдромов. Онкогематология 2018;13(1):63–72. DOI: 10.17650/1818-8346-2018-13-1-63-72.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><mixed-citation>Wells D.A., Benesch M., Loken M.R. et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102(1):394–403. DOI: 10.1182/blood-2002-09-2768. PMID: 12649150.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>van de Loosdrecht A.A., Alhan C., Bene M.C. et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009;94(8):1124–34. DOI: 10.3324/haematol.2009.005801. PMID: 19546437.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Westers T.M., Ireland R., Kern W. et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012;26(7):1730–41. DOI: 10.1038/leu.2012.30. PMID: 22307178.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Porwit A., van de Loosdrecht A.A., Bettelheim P. et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014;28(9):1793–8. DOI: 10.1038/leu.2014.191. PMID: 24919805.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ogata K., Kishikawa Y., Satoh C. et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in lowgrade myelodysplastic syndromes. Blood 2006;108(3):1037–44. DOI: 10.1182/blood-2005-12-4916. PMID: 16574954.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>van de Loosdrecht A.A., Westers T.M. Cutting edge: flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw 2013;11(7):892–902. PMID: 23847222.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Chu S.C., Wang T.F., Li C.C. et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 2011;35(7):868–73. DOI: 10.1016/j.leukres.2011.02.016. PMID: 23847222.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cremers E.M.P., Westers T.M., Alhan C. et al. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. Eur J Cancer 2016;54:49–56. DOI: 10.1016/j.ejca.2015.11.013. PMID: 26720403</mixed-citation></ref></ref-list></back></article>
